CapVest Eyes €10 Billion Stada Buyout, Challenging Pharma's Private Equity Boom

CapVest Partners, the London-based private equity outfit, is reportedly in talks to acquire a controlling stake in German pharmaceutical company Stada Arzneimittel (ETR: STADA). Sources suggest the deal could peg Stada's valuation close to €10 billion ($11.75 billion), debt included.

The current majority owners of Stada, Bain Capital and Cinven, are said to be negotiating the terms with CapVest. Meanwhile, Stada itself hasn't ruled out going public again-an IPO remains on the table as an alternative to a sale.

Stada operates in the generic and over-the-counter drug market, a sector that has drawn strong interest from private equity firms looking for stable cash flows. CapVest's involvement signals another move in pharma consolidation, where established players attract buyout firms aiming for scale or portfolio diversification.

What's particularly interesting is the potential price tag. A near €10 billion valuation implies robust investor confidence in Stada's growth outlook despite increasing competition in generics. It raises the question: is the premium a nod to Stada's market positioning, or is it a bet on operational restructuring under CapVest's management?

No official word yet on the timeline or exact terms. But if CapVest pulls this off, it'll mark one of the bigger European pharma deals this year, shaking up ownership in the sector.